Exchange: NASDAQ·Updated 05:49 PM EDT
News
all
press releases
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
Zacks
More News
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Zacks
Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market capitalization of $10.71read more...
Benzinga
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Are Medical Stocks Lagging Concentra Group Holdings Parent, Inc. (CON) This Year?
Here is how Concentra Group (CON) and Cytokinetics (CYTK) have performed compared to their sector so far this year.
Zacks
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks

Advertisement|Remove ads.